Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2022 Feb 11;42(4):728–731. doi: 10.1007/s10875-022-01223-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022

This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.

PMC Copyright notice

Fig. 1 — Uptake and serological response following 2 doses of COVID-19 vaccination in adults under care of the Immunodeficiency Centre for Wales. A Uptake of first (grey, dot-dashed) and second (black, dashed) COVID-19 vaccination; cumulative total of patient cohort with molecularly confirmed SARS-CoV-2 infection (purple, dotted) and subsequent mortality (red, solid). Shielding of clinically extremely vulnerable individuals in Wales was implemented between March and August 2020, directing such individuals to stay at home to protect themselves. B Anti-SARS-CoV-2 spike IgG serum responses elicited by 2 doses of COVID-19 vaccination in individuals under care of the Immunodeficiency Centre for Wales (ICW) assayed using the semi-quantitative EUROIMMUN IgG assay. Vaccine response indicated on the x-axis by sample:calibrator ratio. Titre grading shown reflects assay cut-off and reported criteria used for selection of convalescent plasma therapy at that time. Patients are sub-grouped by clinical diagnosis (22q11- DiGeorge 22q11 deletion syndrome; CID- Combined Immunodeficiency (without defined molecular diagnosis, including Good’s syndrome); CVID- common variable immunodeficiency syndrome; HG- hypogammaglobulinaemia (insufficient to meet criteria for CVID); HGUS- hypogammaglobulinaemia of uncertain significance (not requiring immunoglobulin replacement therapy); SHG- secondary hypogammaglobulinaemia; SpAD- specific antibody deficiency; XLA- X-linked agammaglobulinaemia; IgRT- immunoglobulin replacement therapy products, diluted to simulate in vivo infusion at replacement dosing). Vaccine type indicated by open squares (ChAdOx1-S, AstraZeneca) and filled circles (mRNA, Pfizer)